Article
Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.
JAMA - 1 Jan 2000
Wong J B, Bennett W G, Koff R S, Pauker S G
Abstract excerpt
CONTEXT: Chronic hepatitis C (CHC) infection affects nearly 4 million people in the United States. Treatment with interferon alfa-2b has been limited by its cost and low likelihood of long-term response. OBJECTIVE: To examine the cost-effectiveness of alternative pretreatment management strategie...
Topics
- Adult
- Antiviral Agents
- Biopsy
- Cost-Benefit Analysis
- Decision Support Techniques
- Diagnostic Tests, Routine
- Disease Progression
- Genotype
- Health Care Costs
- Hepacivirus
- Hepatitis C, Chronic
- Humans
- Interferon alpha-2